Investor Overview Press Releases March 18, 2019 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments March 8, 2019 Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019 February 28, 2019 Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg View all » Events Mar 18, 20198:00 AM EDT Q4 2018 Aclaris Therapeutics Inc. Earnings Conference Call Feb 27, 2019 Aclaris Therapeutics, Inc. at 8th Annual Leerink Partners Global Healthcare Conference Jan 7 - Jan 9, 2019 Aclaris Therapeutics, Inc. at 2019 JP Morgan Healthcare Conference View all » Feature presentation Aclaris Therapeutics, Inc 4Q18 R&D overview
March 18, 2019 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
March 8, 2019 Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019
February 28, 2019 Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg
